Dysregulated Tissue Regeneration Following Surgical Injury: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Dysregulated tissue regeneration following surgical injury represents a significant clinical challenge, with implications for patient recovery, morbidity, and long-term outcomes. This review synthesizes current scientific evidence regarding the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management approaches, and therapeutic advances pertaining to abnormal tissue repair post-surgery. Emphasis is placed on the molecular mechanisms underpinning dysregulated regeneration, including aberrant inflammatory responses, impaired cellular signaling, and maladaptive extracellular matrix remodeling. Recent guideline recommendations and expert consensus are integrated to inform best practices for prevention, diagnosis, and intervention. The article concludes with insights into ongoing research and future directions for optimizing tissue healing after surgical trauma.

Introduction

Surgical injury initiates a tightly regulated sequence of events intended to restore tissue integrity. However, when these processes become dysregulated, patients are at risk for impaired healing, excessive fibrosis, chronic inflammation, and adverse functional outcomes. A comprehensive understanding of the mechanisms driving abnormal regeneration post-surgery is critical for clinicians seeking to minimize complications and improve patient care. This review addresses the multifactorial etiology of dysregulated tissue repair, evaluates recent advances in diagnostic and therapeutic modalities, and synthesizes guideline-based recommendations for the management of surgical patients at risk for pathological healing responses.

Epidemiology / Disease Burden

Dysregulated tissue regeneration is an under-recognized but prevalent complication of surgical procedures, affecting an estimated 5–20% of patients depending on the type and complexity of surgery. Common manifestations include hypertrophic scars, keloids, chronic non-healing wounds, and excessive fibrosis, each contributing to prolonged hospitalization, increased healthcare costs, and diminished quality of life. The burden is particularly high in populations with comorbidities such as diabetes, obesity, and advanced age, where impaired regenerative capacity and heightened susceptibility to abnormal healing are well documented. Postoperative fibrosis is a significant cause of morbidity in organ transplantation, abdominal surgery, and orthopedic interventions, further underlining the clinical impact of this phenomenon.

Pathophysiology

The pathogenesis of dysregulated tissue regeneration involves complex interplay between cellular, molecular, and immunological factors. Key mechanisms include aberrant release of pro-inflammatory cytokines (e.g., IL-1β, TNF-α), dysregulation of growth factor signaling (notably TGF-β and PDGF pathways), excessive fibroblast activation, and disrupted balance between matrix synthesis and degradation. Persistent inflammatory cell infiltration prolongs the inflammatory phase, while inadequate resolution leads to chronic tissue damage and scar formation. Additionally, the failure of progenitor cell recruitment and impaired angiogenesis impede proper tissue remodeling. Recent research highlights the centrality of the immune microenvironment, epigenetic modifications, and altered cellular metabolism in driving maladaptive repair processes following surgical trauma.

Risk Factors

Numerous patient- and procedure-related factors predispose to dysregulated regeneration. Patient risk factors include advanced age, diabetes mellitus, peripheral vascular disease, nutritional deficiencies, immunosuppression, and genetic predisposition (e.g., variants in TGF-β or collagen genes). Procedural risk factors encompass the extent of surgical trauma, inadequate hemostasis, infection, ischemia-reperfusion injury, and repeated surgeries at the same site. Recognition of these risk factors allows for stratification of patients who may benefit from targeted preventive measures and close postoperative monitoring.

Clinical Features

Clinically, dysregulated tissue regeneration manifests as delayed wound healing, persistent pain, abnormal scar formation (hypertrophic scars, keloids), contractures, and in severe cases, organ-specific dysfunction (e.g., restrictive pulmonary fibrosis or intra-abdominal adhesions). Patients may present with erythema, swelling, induration, and altered tissue texture at the surgical site. Chronic wounds are characterized by failure to progress through normal healing stages, while excessive fibrosis can result in reduced tissue compliance and impaired organ function. Early recognition of these features is essential for timely intervention.

Diagnosis

Diagnosis relies on a combination of clinical assessment and adjunctive investigations. Detailed patient history and examination are paramount. Imaging modalities, such as high-frequency ultrasound, MRI, or CT, assist in characterizing tissue architecture, extent of fibrosis, and identifying occult abscesses or foreign bodies. Histopathological analysis of tissue biopsies provides definitive evidence of abnormal cellular and extracellular matrix composition. Biomarkers including elevated serum TGF-β, markers of oxidative stress, and specific microRNAs are under investigation for their utility in early detection of dysregulated regeneration.

Treatment & Management

Management strategies are multidisciplinary and tailored to the underlying pathology. Initial measures include infection control, optimization of glycemic status, and nutritional support. Local wound care with advanced dressings, negative pressure wound therapy, and debridement are standard for chronic wounds. Intralesional corticosteroids, topical silicone, and pressure therapy are utilized for hypertrophic scars and keloids. In cases of excessive fibrosis, antifibrotic agents (e.g., pirfenidone, pentoxifylline) and physical therapy are considered. Surgical revision may be warranted for refractory cases but carries risk of recurrence. Patient education and psychosocial support are integral, particularly for those with disfiguring scars or functional impairment.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel therapeutic approaches targeting the molecular drivers of dysregulated regeneration. Biologic agents such as monoclonal antibodies against TGF-β and inhibitors of connective tissue growth factor have shown promise in preclinical and early clinical studies. Stem cell therapies, including mesenchymal stromal cell transplantation, aim to restore normal tissue architecture and modulate the immune response. Gene editing technologies and RNA-based therapeutics represent cutting-edge modalities for correcting underlying genetic and epigenetic aberrations. Additionally, the use of bioengineered scaffolds and 3D-printed tissue constructs offers new avenues for regenerative repair, particularly in complex wound environments. Ongoing clinical trials are expected to refine the efficacy and safety profiles of these innovative therapies.

Guideline Recommendations

Current clinical guidelines emphasize a risk-based approach to the prevention and management of dysregulated tissue regeneration. The use of perioperative glycemic control, prophylactic antibiotics, and meticulous surgical technique are strongly recommended. Early involvement of wound care specialists, individualized rehabilitation protocols, and prompt intervention for complications are endorsed. For patients at high risk of pathological scarring, guidelines advocate the use of silicone therapy, pressure garments, and regular follow-up. Multidisciplinary collaboration between surgeons, wound care nurses, rehabilitation specialists, and dermatologists is vital for optimizing outcomes. Adherence to evidence-based protocols and patient-centered care remains the cornerstone of effective management.

Conclusion

Dysregulated tissue regeneration following surgical injury is a multifaceted clinical problem with significant implications for postoperative recovery and long-term health. Advances in understanding the molecular and cellular mechanisms underlying pathological healing have informed the development of targeted therapies and refined management strategies. Early recognition, risk stratification, and adherence to guideline-based interventions are essential for minimizing complications and enhancing patient outcomes. Continued research into innovative therapies and precision medicine approaches holds promise for further improving the care of patients experiencing abnormal tissue regeneration after surgery.